Ionis Pharmaceuticals (IONS) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Cerebras Systems hits new 52-week low on unlock concerns
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
Ionis reports first quarter 2020 financial results and recent business achievements
May 6, 2020 7:00 AM EDTCARLSBAD, Calif., May 6, 2020 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2020 and recent business highlights.
"We achieved numerous value-driving catalysts in the first quarter, setting us up to... More



